| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/18/2006 | US7029914 DNA encoding SNORF36 receptors |
| 04/18/2006 | US7029877 binding protease thrombin to phosphoethanolamine binding protein |
| 04/18/2006 | US7029860 Amyloid-β protein aggregation-regulating factors |
| 04/18/2006 | US7029710 For inhibiting amyloid formation, deposition, accumulation, or persistence, or amyloid protein-amyloid protein interactions, amyloid-proteoglycan interactions, amyloid-PG/GAG interactions and/or amyloid-glycosaminoglycan interactions |
| 04/18/2006 | US7029707 Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| 04/18/2006 | US7029692 content of monoterpene ketone in the nicotine-containing layer is 0.1 to 5.0%-wt of the weight; masks the unpleasant smell of nicotine |
| 04/18/2006 | US7029674 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1 |
| 04/18/2006 | US7029663 substantially anhydrous, using hydrocarbon gel and/or petrolatum as a base; increased storage stability |
| 04/18/2006 | US7029658 Delivery of antidepressants through an inhalation route |
| 04/18/2006 | CA2431683C Migraine headache eye-rinse remedy solution |
| 04/18/2006 | CA2346335C Sertraline oral concentrate |
| 04/18/2006 | CA2155666C Novel derivatives of 3-hydroxy anthranilic acid, methods and intermediates for their preparation, novel pharmaceutical compositions and the use thereof |
| 04/13/2006 | WO2006038738A1 Receptor function regulating agent |
| 04/13/2006 | WO2006038729A1 Mutated amyloid protein |
| 04/13/2006 | WO2006038680A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 04/13/2006 | WO2006038594A1 N-type calcium channel inhibitor |
| 04/13/2006 | WO2006038528A1 Composition and method for therapy or prevention of mental symptom |
| 04/13/2006 | WO2006038084A1 Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression |
| 04/13/2006 | WO2006038006A2 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders |
| 04/13/2006 | WO2006037604A1 Novel antibodies directed to the mammalian eag1 ion channel protein |
| 04/13/2006 | WO2006037482A2 Compositions and methods for treating cognitive disorders |
| 04/13/2006 | WO2006037481A1 Benzoxazine and quinoxaline derivatives and uses |
| 04/13/2006 | WO2006005802A8 Method for stimulating mammalian cells and mammalian cell |
| 04/13/2006 | WO2006004931A3 Substituted azepine derivatives as serotonin receptor modulators |
| 04/13/2006 | WO2005105066A8 Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases |
| 04/13/2006 | WO2005087752A3 Substituted hydroxyethylamine aspartyl protease inhibitors |
| 04/13/2006 | WO2005067893A3 Pharmaceutical compositions comprising midazolam in a high concentration |
| 04/13/2006 | US20060079713 Novel salt forms of poorly soluble probucol esters and ethers |
| 04/13/2006 | US20060079707 Cyclization by reacting 4-(2-CHLORO-4-TRIFLUOROMETHYL-PHENYL)-4-CYANO-BUT-3-ENOIC ACID METHYL ESTER in the presence of a palladium catalyst and a base; chemical intermediates for preparing 10-AZA-TRICYCLO[6.3.1.02,7] drugs; bind nicotinic acetylcholine receptor, modulate cholinergic function |
| 04/13/2006 | US20060079670 98 human secreted proteins |
| 04/13/2006 | US20060079570 Alpha-aminoamide derivatives useful as antimigraine agents |
| 04/13/2006 | US20060079563 Cyclic protein tyrosine kinase inhibitors |
| 04/13/2006 | US20060079555 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 04/13/2006 | US20060079554 Inhibitors of monomine uptake |
| 04/13/2006 | US20060079551 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| 04/13/2006 | US20060079550 Amino acid derivatives useful for the treatment of alzheimer's disease |
| 04/13/2006 | US20060079548 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
| 04/13/2006 | US20060079533 Methods of treating alzheimer's disease |
| 04/13/2006 | US20060079529 6-7-8-9-Tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime derivatives such as 5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime; sodium channel modulators; antiischemic agents |
| 04/13/2006 | US20060079527 Compounds such as 1-[4-(3,4-difluoro-phenyl) -piperazin-1 -yl]-3-{methyl-[2-(9H-xanthen-9-yl)-ethyl]-amino}-propan-1 -one in free base or acid addition salt form, for therapy of depression, anxiety and bipolar disorders |
| 04/13/2006 | US20060079525 antiinflammatory agent N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}cyclopropane carboxamide; bronchitis, asthma, chronic obstructive pulmonary disease and rhinitis |
| 04/13/2006 | US20060079503 Thiazolidinones and the use therof as polo-like kinase inhibitors |
| 04/13/2006 | US20060079502 Pharmaceutical compositions |
| 04/13/2006 | US20060079499 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 04/13/2006 | US20060079451 Heparin-binding proteins modified with sugar chains, method of producing the same and pharmaceutical compositions containing same |
| 04/13/2006 | US20060078989 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 04/13/2006 | US20060078956 Methods to identify compounds that modulate rage |
| 04/13/2006 | US20060078918 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator |
| 04/13/2006 | US20060078901 Listeria monocytogenes genome, polypeptides and uses |
| 04/13/2006 | US20060078878 Cell containing nucleic acid molecule comprising polynucleotide sequence encoding engineered zinc finger protein operably linked to promoter, contacting target site in endogenous cellular gene with protein to inhibit transcription |
| 04/13/2006 | US20060078613 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
| 04/13/2006 | US20060078547 Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants are useful in the prophylaxis and/or treatment undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome |
| 04/13/2006 | US20060078545 Neural progenitor cell populations |
| 04/13/2006 | US20060078543 Neural progenitor cells derived from embryonic stem cells |
| 04/13/2006 | CA2583431A1 Variant amyloid protein |
| 04/13/2006 | CA2583326A1 Receptor function regulating agent |
| 04/13/2006 | CA2583287A1 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders |
| 04/13/2006 | CA2582683A1 Novel antibodies directed to the mammalian eag1 ion channel protein |
| 04/13/2006 | CA2582327A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 04/13/2006 | CA2582273A1 Compositions and methods for treating cognitive disorders using serotonin receptor antagonists |
| 04/13/2006 | CA2581921A1 Benzoxazine and quinoxaline derivatives and uses |
| 04/13/2006 | CA2581564A1 Compounds that modulate trh actions |
| 04/13/2006 | CA2562151A1 Oligonucleotides comprising a c5-modified pyrimidine |
| 04/13/2006 | CA2561993A1 Compositions and methods for modulating gated ion channels |
| 04/12/2006 | EP1646131A1 Dc motor |
| 04/12/2006 | EP1645624A1 Nerve cells obtained by electrical pulse treatment es cell |
| 04/12/2006 | EP1645558A1 Piperazinylpyrazines as serotonin 5-HT2C receptor modulators |
| 04/12/2006 | EP1645288A1 New nuclear transcription factors regulators |
| 04/12/2006 | EP1645286A1 Drug for nerve regeneration |
| 04/12/2006 | EP1645285A2 Therapeutical use of anti-mag antibody for the treatment of ischemic stroke |
| 04/12/2006 | EP1645277A1 Stable tetrodotoxin freeze drying medicinal preparation |
| 04/12/2006 | EP1645276A1 Treatment of neurodegenerative disorders |
| 04/12/2006 | EP1645273A2 Novel use of (R)-(-)-2-(5-(-flourophenyl)-3-pyridylmethylaminoethyl|-chromane and its physiologically acceptable salts |
| 04/12/2006 | EP1645272A2 Daidzin derivatives for the treatment of alcohol dependence or alcohol abuse |
| 04/12/2006 | EP1645270A2 Control of pain with endogenous cannabinoids |
| 04/12/2006 | EP1644742A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| 04/12/2006 | EP1644351A1 Imidazole derivatives iii |
| 04/12/2006 | EP1644339A1 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors |
| 04/12/2006 | EP1644328A1 Sulfonamide derivatives as 5ht7 receptor antagonists |
| 04/12/2006 | EP1644323A2 Histone deacetylase inhibitors and methods of use thereof |
| 04/12/2006 | EP1644322A1 Aspartyl protease inhibitors |
| 04/12/2006 | EP1644320A1 Indane derivates as muscarinic receptor agonists |
| 04/12/2006 | EP1644064A1 Dispenser with reservoir containing a drug of abuse |
| 04/12/2006 | EP1644026A2 Sigma ligands for neuronal regeneration and functional recovery |
| 04/12/2006 | EP1644019A1 Abuse resistant amphetamine compounds |
| 04/12/2006 | EP1644009A2 Compositions and methods for increasing telomerase activity |
| 04/12/2006 | EP1644005A1 Metabolite of quetiapine |
| 04/12/2006 | EP1644000A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 04/12/2006 | EP1643998A1 Dual nk1/nk3 antagonists for treating schizophrenia |
| 04/12/2006 | EP1643994A2 Methods for inhibiting or reversing tau filament fibrillization |
| 04/12/2006 | EP1643985A1 The combination of a serotonin reuptake inhibitors and agomelatine |
| 04/12/2006 | EP1546151B1 Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
| 04/12/2006 | EP1511747B1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 04/12/2006 | EP1476444B1 Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
| 04/12/2006 | EP1423436B1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids |
| 04/12/2006 | EP1404671B1 Macrocycles useful in the treatment of alzheimer's disease |
| 04/12/2006 | EP1355639B1 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists |
| 04/12/2006 | EP1345920B1 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/12/2006 | EP1331940B1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 04/12/2006 | EP1325335B1 Methods for diagnosing and treating huntington's disease |